Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.

por Erba, E., Sen, S., Sessa, C., Vikhanskaya, F. L., D'Incalci, M.
Publicado 1994

Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.

por Morasca, L., Erba, E., Vaghi, M., Ghelardoni, C., Mangioni, C., Sessa, C., Landoni, F., Garattini, S.
Publicado 1983

Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer

por Ghielmini, M, Pagani, O, Jong, J de, Pampallona, S, Conti, A, Maestroni, G, Sessa, C, Cavalli, F
Publicado 1999

Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores

por Broekman, K.E., van Kruchten, M., van Tinteren, H., Sessa, C., Jalving, M., Reyners, A.K.L.
Publicado 2021

Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins

por Proebstle, T M, Alm, B J, Göckeritz, O, Wenzel, C, Noppeney, T, Lebard, C, Sessa, C, Creton, D, Pichot, O
Publicado 2015

Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells.

por Ghielmini, M., Bosshard, G., Capolongo, L., Geroni, M. C., Pesenti, E., Torri, V., D'Incalci, M., Cavalli, F., Sessa, C.
Publicado 1997

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

por Sulkes, A., Smyth, J., Sessa, C., Dirix, L. Y., Vermorken, J. B., Kaye, S., Wanders, J., Franklin, H., LeBail, N., Verweij, J.
Publicado 1994

Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies

por Leyvraz, S, Herrmann, R, Guillou, L, Honegger, H P, Christinat, A, Fey, M F, Sessa, C, Wernli, M, Cerny, T, Dietrich, D, Pestalozzi, B
Publicado 2006

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

por Del Conte, G, Sessa, C, von Moos, R, Viganò, L, Digena, T, Locatelli, A, Gallerani, E, Fasolo, A, Tessari, A, Cathomas, R, Gianni, L
Publicado 2014

The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective

por Sessa, C., Cortes, J., Conte, P., Cardoso, F., Choueiri, T., Dummer, R., Lorusso, P., Ottmann, O., Ryll, B., Mok, T., Tempero, M., Comis, S., Oliva, C., Peters, S., Tabernero, J.
Publicado 2021

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

por Colombo, N, McMeekin, D S, Schwartz, P E, Sessa, C, Gehrig, P A, Holloway, R, Braly, P, Matei, D, Morosky, A, Dodion, P F, Einstein, M H, Haluska, F
Publicado 2013

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

por Garrido, P., Adjei, A.A., Bajpai, J., Banerjee, S., Berghoff, A.S., Choo, S.P., Felip, E., Furness, A.J.S., Garralda, E., Haanen, J., Letsch, A., Linardou, H., Peters, S., Sessa, C., Tabernero, J., Tsang, J., Yang, J.C-.H., Garassino, M.C.
Publicado 2021

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

por Berghoff, A.S., Sessa, C., Yang, J.C.-H., Tsourti, Z., Tsang, J., Tabernero, J., Peters, S., Linardou, H., Letsch, A., Haanen, J., Garralda, E., Garassino, M.C., Furness, A.J.S., Felip, E., Dimopoulou, G., Dafni, U., Choo, S.P., Banerjee, S., Bajpai, J., Adjei, A.A., Garrido, P.
Publicado 2021

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

por Linardou, H., Adjei, A.A., Bajpai, J., Banerjee, S., Berghoff, A.S., Mathias, C. Cerqueira, Choo, S.P., Dent, R., Felip, E., Furness, A.J.S., Garassino, M.C., Garralda, E., Konsoulova-Kirova, A., Letsch, A., Menzies, A.M., Mukherji, D., Peters, S., Sessa, C., Tsang, J., Yang, J.C.-H., Garrido, P.
Publicado 2023

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/...

por Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D’Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A.
Publicado 2023